# Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

> **NCT01679964** · PHASE4 · COMPLETED · sponsor: **Lin, Hsi-Hsun, M.D.** · enrollment: 107 (actual)

## Conditions studied

- HIV Infection
- Adverse Drug Reaction
- Quality of Life

## Interventions

- **DRUG:** Raltegravir switch

## Key facts

- **NCT ID:** NCT01679964
- **Lead sponsor:** Lin, Hsi-Hsun, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679964, "Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01679964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*